Adar Poonawalla: News
'Kabhi Khushi Kabhie Gham' was once sold for just $5,000
Renowned filmmaker Karan Johar has made a grand return to the Cannes Film Festival after 12 years. The director is at the festival to promote his latest production, Homebound, directed by Neeraj Ghaywan.
Why Gippy Grewal's 'Akaal' is facing backlash in Punjab
Singer and actor Gippy Grewal's latest film, Akaal: The Unconquered, which was released on Thursday, has courted controversy in Punjab for its portrayal of the Sikh community.
Dharma Productions expands into regional cinema
Karan Johar's Dharma Productions, in association with Adar Poonawalla, has launched a new venture to make its mark in the regional cinema.
Adar Poonawalla acquires 20% stake in online auction house AstaGuru
Adar Poonawalla, a well-known art and fine collectibles aficionado, has made a strategic investment via his family office to buy around 20% stake in AstaGuru.
After selling 50% of Dharma, KJo enters film distribution: Report
Karan Johar, the ace filmmaker and head of Dharma Productions, is reportedly venturing into the film distribution business.
KJo felt 'traumatized' during Dharma deal meetings with Adar Poonawalla
Renowned filmmaker Karan Johar recently opened up about selling a major stake in his company, Dharma Productions, to Serum Institute's CEO Adar Poonawalla.
Shockingly bad business forced Karan Johar to sell Dharma stake
Earlier this month, Adar Poonawalla picked up a 50% stake in Karan Johar's Dharma Productions for ₹1,000cr. The move had fueled speculation about the financial health of one of India's most influential production houses.
Adar Poonawalla acquires half of KJo's Dharma Productions for ₹1,000cr
In a major development, Adar Poonawalla, the CEO of Serum Institute of India, will be buying a 50% stake in Dharma Productions and Dharmatic Entertainment.
Serum Institute partners with Oxford University to combat Meningitis-B
The Serum Institute of India has entered into a five-year licensing deal with the University of Oxford, according to a press release on Tuesday (April 16).
Adar Poonawalla buys London's most expensive house for Rs. 1,446cr
Billionaire Adar Poonawalla, the CEO of Serum Institute of India (SII), has reportedly finalized a deal to buy London's priciest house sold this year, worth £138 million (Rs. 1,446 crore).
Serum Institute seeks DCGI's approval for Covovax as booster dose
The Serum Institute of India (SII) has sought the Drugs Controller General of India's (DCGI) approval to roll out its Covovax in the market as a booster dose for adults.
Covishield manufacturer SII duped of Rs. 1 crore, 7 arrested
In a major cheating and cyber fraud case, the Serum Institute of India (SII) has been duped of Rs. 1 crore.
Is SII developing vaccine for monkeypox? Here's what Poonawalla said
Amid the rising monkeypox scare, Serum Institute of India (SII) CEO Adar Poonawalla said on Tuesday they are in talks with American biotech company Novavax to develop a messenger RNA (mRNA) vaccine for it.
Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla
Billions need to be vaccinated at a faster rate to reach the end of the COVID-19 pandemic, said Adar Poonawalla, CEO of the Serum Institute of India (SII), which manufactures the COVID-19 vaccine Covishield.
SII to launch COVID-19 vaccine for children in 6 months
The Serum Institute of India is looking to launch a COVID-19 vaccine for children in six months, SII CEO Adar Poonawalla said Tuesday.
EU body says it didn't receive application for Covishield approval
The European Medicines Agency (EMA) said it has not received any application for the authorization of the coronavirus vaccine Covishield.
Serum to begin Covovax trials on children in July
The Serum Institute of India (SII) will soon apply for regulatory approval to conduct clinical trials of Covovax on children in India.
Covovax India launch by September; trial for kids soon: SII
The Serum Institute of India (SII) is looking to launch the COVID-19 vaccine developed by the United States firm Novavax in India by September.
Reports claiming fresh COVID-19 vaccine orders not placed baseless: Government
The Union Health Ministry on Monday refuted media reports that claimed that the central government had not placed fresh orders for COVID-19 vaccines.
Getting aggressive calls from powerful people: SII CEO Adar Poonawalla
Serum Institute of India CEO Adar Poonawalla has revealed that his decision to fly to London when India is facing a COVID-19 second wave was largely due to the threats he had been facing.
Covishield price reduced to Rs. 300 for states: Adar Poonawalla
Adar Poonawalla, the CEO of the Serum Institute of India (SII), on Wednesday announced that the price of the COVID-19 vaccine Covishield was being reduced from Rs. 400 to Rs. 300 for states.
COVID-19 vaccine production hit as US, Europe obstruct raw material
As India faces a record surge in coronavirus infections, Serum Institute of India (SII) CEO Adar Poonawalla has raised concerns about the United States and Europe holding back key vaccine raw material.
AstraZeneca serves legal notice to Serum Institute over vaccine delays
Serum Institute of India (SII), the manufacturer of the coronavirus vaccine Covishield, has been served a legal notice by the drug maker AstraZeneca over delays in vaccine supply, the company's CEO Adar Poonawalla confirmed in an interview earlier this week.
Covishield 90% effective if doses given 2-3 months apart: Poonawalla
The efficacy of the COVID-19 vaccine Covishield could increase to 90% if the two doses are given 2.5-3 months apart, Serum Institute of India CEO Adar Poonawalla said Monday.
Serum CEO Poonawalla hopes to launch second vaccine by September
Serum Institute of India CEO Adar Poonawalla today said that his company hopes to launch its second coronavirus vaccine by September this year.
Adar Poonawalla, WHO scientist warn of delays in vaccine production
Adar Poonawalla, the head of the world's biggest vaccine maker, and the World Health Organization's (WHO) chief scientist have said that the manufacturers of coronavirus vaccine doses are facing a global shortage of the raw materials required to produce the doses.
After SII fire, BCG, rotavirus vaccine production to be hit
Thursday's fire at Pune's Serum Institute of India will impact the production of BCG and rotavirus vaccines in the future, the company said on Friday.
Pune: Fire breaks out at Serum Institute of India
On Thursday afternoon, a fire broke out at the Terminal 1 gate of Serum Institute of India, Pune.
Rs. 200 per vaccine dose: SII receives government's purchase order
The Pune-based Serum Institute of India (SII) has received the purchase order for COVID-19 vaccines from the central government, officials said on Monday.
SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
The Serum Institute of India (SII) and Bharat Biotech have taken a joint pledge to ensure global access of the COVID-19 vaccines developed by them.
Private hospitals may get coronavirus vaccine by March: Serum CEO
While the Indian government has prioritized healthcare workers and high-risk individuals in its vaccine program, doses of the coronavirus vaccine will be available for private companies, hospitals, and individuals by as early as March, the CEO of Serum Institute of India (SII), Adar Poonawalla, said on Sunday.
'Finally paid off,' says Adar Poonawalla after Covishield gets approval
Serum Institute of India's (SII) chief Adar Poonawalla today wished everyone a happy new year along with a great announcement.
Applying for Covishield's emergency approval in 2 weeks: SII
The CEO of the Serum Institute of India (SII), Adar Poonawalla, on Saturday said that the company will seek the emergency-use authorization of the coronavirus vaccine 'Covishield' soon.
Can launch 100 million vaccine doses by January-February, says Poonawalla
The CEO of the Serum Institute of India (SII), Adar Poonawalla, has said that the institute can roll out 100 million doses of the COVID-19 vaccine by January-February.
Oxford vaccine to be available by April 2021 in India
Pune-based Serum Institute of India, which has partnered with Oxford University and British pharma giant AstraZeneca, plans to seek an emergency approval from the government of India next month, for providing the coronavirus vaccine to "corona warriors" and the elderly.
India to get 10cr COVID-19 vaccine doses by December: SII
The Serum Institute of India is hoping to produce 100 million (10 crore) doses of AstraZeneca and Oxford University's COVID-19 vaccine, CEO Adar Poonawalla said.
Vaccine tracker: Covishield trials running smoothly; COVAXIN expected by February
Even as the COVID-19 outbreak has witnessed a downward trend in India, some states have been reporting large spikes in infections, indicating that the pandemic is far from over.
Affordable COVID-19 vaccine by January 2021, promises SII's Adar Poonawalla
Adar Poonawalla, the CEO of Serum Institute of India, said that the vaccine against coronavirus will be available in India by January 2021, two months from now, provided that the government gives approvals on time.
Vaccine tracker: Covishield expected by December; Moderna readies for launch
It has been almost a year since the coronavirus pandemic began, yet the virus is far from being brought under control.
PM's vaccine arrangements will take care of all: Adar Poonawalla
As India's COVID-19 vaccine strategy becomes a point of debate, Adar Poonawalla has expressed confidence over Prime Minister Narendra Modi's vision to protect Indian citizens from the ongoing pandemic.
After setback, Serum allowed to resume Oxford's coronavirus vaccine trial
Drugs Controller General of India (DCGI) Dr. VG Somani has permitted the Serum Institute of India (SII) to resume trial of the coronavirus vaccine candidate, being developed by the University of Oxford, revoking the last week's order that halted the process.
Coronavirus vaccine won't be available for all before 2024-end: Poonawalla
Adar Poonawalla, the CEO of the Serum Institute of India (SII), that has taken up the mammoth task of mass-producing the vaccine for novel coronavirus, asserted that the vaccine will not be available for the entire world before the end of 2024.
India: Serum Institute's COVID-19 vaccine goes into Phase-2/3 trials
In a major development, Adar Poonawalla's Serum Institute of India has started the Phase-2/3 trial of a promising COVID-19 vaccine licensed from AstraZeneca and Oxford University.
India likely to have COVID-19 vaccine by December: Adar Poonawalla
India should have a vaccine to exit the COVID-19 pandemic by the end of this year.
Oxford's COVID-19 vaccine: India readies five sites for human trials
India has prepared five sites for the final human trials phase of the potential COVID-19 vaccine developed by Oxford University, reports PTI.
Meet Adar Poonawalla, the man bringing COVID-19 vaccines to India
In the fight against COVID-19, or should we say the worst health crisis of our time, several institutes/organizations are racing to develop vaccines, anti-viral treatments.
Coronavirus vaccine will be available by 2021? Adar Poonawalla hopeful
Adar Poonawalla, the chief of Serum Institute of India (SII), is hoping that vaccine to fight coronavirus will be available in India by the first quarter of 2021.
India will start COVID-19 vaccine production next month: Details here
In a major development, Cyrus S. Poonawalla's Serum Institute of India has confirmed that it will start making a vaccine for COVID-19 next month.